These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6404 related articles for article (PubMed ID: 3496972)

  • 1. Inverse relationship in H-2-associated lysis between NK cells and rIL-2-activated killer cells: evidence from in vitro killing and metastatic experiments.
    Toshitani A; Taniguchi K; Kawano Y; Nomoto K
    Cell Immunol; 1987 Aug; 108(1):188-202. PubMed ID: 3496972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF impairs in vivo and in vitro natural killer (NK) susceptibility of B16 melanoma cells.
    Palmieri G; Morrone S; Lollini PL; De Giovanni C; Nicoletti G; Nanni P; Frati L; Santoni A
    Scand J Immunol; 1992 Mar; 35(3):279-87. PubMed ID: 1535986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
    Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F; Basse PH; Hokland M
    Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-metastatic effect by in vivo administration of concanavalin A through augmentation of T-derived activated killer activity: efficacy to B16 melanoma expressed MHC antigen.
    Taniguchi K; Kawano YI; Toshitani A; Karashima A; Nomoto K
    Cell Immunol; 1989 May; 120(2):460-9. PubMed ID: 2785862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precursor phenotype of lymphokine-activated killer cells in the mouse.
    Salup RR; Mathieson BJ; Wiltrout RH
    J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells.
    Merluzzi VJ; Smith MD; Last-Barney K
    Cell Immunol; 1986 Jul; 100(2):563-9. PubMed ID: 3489533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection.
    Weinberg A; Basham TY; Merigan TC
    J Immunol; 1986 Nov; 137(10):3310-7. PubMed ID: 3021853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2-associated control: different behavior of H-2+ and H-2- cells in metastatic processes.
    Kawano Y; Taniguchi K; Toshitani A; Nomoto K
    J Immunol; 1986 Jun; 136(12):4729-34. PubMed ID: 3711664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine trophoblast can be killed by lymphokine-activated killer cells.
    Drake BL; Head JR
    J Immunol; 1989 Jul; 143(1):9-14. PubMed ID: 2499634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung colonization and metastasis by disseminated B16 melanoma cells: H-2 associated control at the level of the host and the tumor cell.
    Taniguchi K; Kärre K; Klein G
    Int J Cancer; 1985 Oct; 36(4):503-10. PubMed ID: 4044058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 321.